Dr David Tan is a medical oncologist and clinician scientist at the National University Cancer Institute, Singapore. He is an Associate Professor at the Yong Loo Lin School of Medicine, NUS and Principal Investigator at the Cancer Science Institute, NUS. He is also Head of the Innovation Transfer Office at National University Health Systems (NUHS). His primary clinical and research interests are in gynaecological (ovarian, endometrial and cervical) cancers and the development of novel anti-cancer therapeutic agents.
Dr Tan graduated from Guy’s, King’s and St Thomas’ School of Medicine, University of London, UK with a BSc in Experimental Pathology (1st Class Honours) and MBBS with Distinction. He undertook training in internal medicine at Hammersmith Hospital and Guy’s and St Thomas’ Hospitals in London before being awarded a Cancer Research UK Research Fellowship at The Institute of Cancer Research in London, where he obtained his PhD in Oncology. He subsequently completed his specialist training in medical oncology at The Royal Marsden Hospital in London. After working in the Drug Development Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he completed another fellowship at the Princess Margaret Cancer Centre, University of Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning back to Singapore.
He is the founding President of the Gynecologic Cancer Group Singapore (GCGS), which is a national clinical trials network for gynaecologic cancers in Singapore, and was the inaugural Chairman of the Asia-Pacific Gynaecologic Oncology Trials (APGOT) Group from 2019-2022. He currently also co-chairs the Cervical Cancer Research Network (CCRN) of the Gynecologic Cancer InterGroup (GCIG) and sits on the Gynecologic Cancer InterGroup (GCIG) Executive Board of Directors.
